Vimarsana
Biggest News Aggregation in the World

Page 2 - Prolacta Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Prolacta Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Prolacta Bioscience Today - Breaking & Trending Today

Prolacta's Human Milk-Based Nutrition Has Touched the Lives of 100,000 Premature and Critically Ill Infants Globally - Vimarsana News

Prolacta's Human Milk-Based Nutrition Has Touched the Lives of 100,000 Premature and Critically Ill Infants Globally

/PRNewswire/ -- Prolacta Bioscience, the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants,...

Phase 2a Trial Uses Human Milk-Based Therapy for Blood Cancer - Vimarsana News

Phase 2a Trial Uses Human Milk-Based Therapy for Blood Cancer

City of Hope researchers initiated groundbreaking Phase 2a trial using human milk-based therapy for blood cancer patients undergoing stem cell transplantation.

Study: Precision microbiome engineering - Vimarsana News

Study: Precision microbiome engineering

Bacteria found in the gut of nursing infants combined with breast milk sugars may lead to live biotherapeutics and ultimately be a game-changer for the gut health of adults.

Study: Precision microbiome engineering - Vimarsana News

Study: Precision microbiome engineering

Bacteria found in the gut of nursing infants combined with breast milk sugars may lead to live biotherapeutics and ultimately be a game-changer for the gut health of adults.

New Study Shows Prolacta's Human Milk-Based Nutritional Fortifiers Save Hospital NICUs Up to $3.4M Annually - Vimarsana News

New Study Shows Prolacta's Human Milk-Based Nutritional Fortifiers Save Hospital NICUs Up to $3.4M Annually

/PRNewswire/ -- Prolacta Bioscience, the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants,...